Navigation Links
NIH grant advances Tay-Sachs disease gene therapy
Date:8/27/2009

Chestnut Hill, Mass. (August 27, 2009) In a victory for families who dug into their own pockets to fund new research, the National Institutes of Health has awarded a $3.5-million grant to the Boston-based Tay-Sachs Gene Therapy Consortium to prepare a gene therapy for human clinical trials in a bid to halt the fatal genetic disorder.

With a plan to initiate human trials within four years, the NIH award was eagerly awaited by Tay-Sachs families and their supporters, who raised nearly $600,000 to assemble the international consortium of experts and help maintain its research agenda while scientists worked to secure federal funding. The NIH grant will help advance the gene therapy from animal tests to human clinical trials.

"The consortium has been held together with funds raised by people affected by this terrible disease," said Boston College Professor of Biology Thomas Seyfried, whose lab is part of the consortium. "People were pounding the pavement raising money. It was critical to our work and for these families, who have lost children, who have a vested interest in this research."

In addition to the Seyfried lab, the consortium includes University of Massachusetts Medical School professor and project manager Miguel Sea-Esteves, Dr. Tim Cox, University of Cambridge (U.K.), Dr. Florian Eichler, Massachusetts General Hospital, and Auburn University Professor Doug Martin.

"We see this as a tremendous achievement," said Susan Kahn, executive director of the Boston-based National Tay-Sachs and Allied Diseases Association, which made establishing the consortium a top research priority. "Without the initial funding from families and donors, we might never have seen this day come. While we know much work lies ahead, the potential success of this gene therapy effort can ultimately go way beyond Tay-Sachs to other diseases that affect the brain."

A fatal genetic disorder most often found in children of Eastern European Jewish descent, Tay-Sachs typically claims its victims before they reach age 5. There are variants that affect children of Irish and French-Canadian descent as well. While genetic screening has greatly reduced deaths from Tay-Sachs, approximately 25-30 individuals die from the disease annually.

Infants can show signs of the disease as early as six months, cease meeting developmental milestones, and then begin to lose motor skills. Children affected by juvenile onset show signs after age three and quickly begin to regress physically and mentally. Most children do not survive past age 5. For adults afflicted by late onset Tay-Sachs, symptoms are often confused with mental illness or other diagnoses.

Tay-Sachs disease creates an enzyme deficiency that allows harmful quantities of a fatty substance, or lipid, to build up in the nerve cells of the brain, resulting in a relentless deterioration of mental and physical abilities. Consortium researchers say their therapy will battle the disease at the cellular level.

The consortium was formed two years ago as researchers refined a viral vector injection capable of delivering two human genes known as HexA and HexB which are deficient in Tay-Sachs. Injection of cells in the brain through two individual vectors has been shown in laboratory mice to spur production of normal enzyme at levels sufficient to correct the enzymatic deficiency throughout the entire brain of these subjects. Consortium researchers have successfully paired the two genes in a single vector, which they believe will result in increased therapeutic efficiency and lower production costs.

The consortium received grants through the National Tay-Sachs and Allied Diseases Association's Research Initiative, which raised the majority of the funds through family foundations: The Cure Tay-Sachs Foundation, the Cameron and Hayden Lord Foundation, the Mathew Forbes Romer Foundation, the Pesotchinsky Family Fund, the Hoffman Family Fund and the Ungerleider Family Fund.

Seyfried's lab at Boston College has been researching Tay-Sachs for 30 years. Five years ago, Seyfried reported tests in mice showed a drug could block the accumulation of fatty substances in the brain. That drug was a small, artificial amino sugar molecule that blocked the initial steps of the disease.


'/>"/>

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College
Source:Eurekalert  

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. TANCS Steam Vapor Granted U.S. Patent
3. New Federal Training Grant to Teach Doctors/Scientists Immunology
4. eDiets.com(R) Granted Continued Listing by NASDAQ Panel
5. The Blue Foundation for a Healthy Florida Receives Grant to Address National/Regional Nursing Shortages
6. The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant
7. The Dannon Company Awards Fourth Annual Dannon Next Generation Nutrition Grants Supporting Nutrition Education for Children
8. Making The Outdoors Safer for Communities: The American Academy of Dermatology Announces 2009 AAD Shade Structure Program Grant Recipients
9. The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms
10. DuPage Community Foundation Awards $15,000 Grant to Marianjoy Pediatric Continuing Care Program
11. The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH grant advances Tay-Sachs disease gene therapy
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: